Since the 1970s, medical ethics has evolved from an informal approach to a more structured public discourse. The 4 principles proposed by Beauchamp and Childress in 1979 have gained international recognition and are useful for organizing ethical issues. However, this methodology has its limitations, and dialogue-based ethics are becoming increasingly important. Healthcare providers face 2 conflicting responsibilities: delaying death and ensuring a peaceful death, which are central to ethical considerations. Additionally, Japan's lack of legal clarity on life-shortening procedures introduces further ethical challenges. The ethical issues in advance care planning(ACP)include:(1)the shift from informal to public discourse ethics, (2)developing a methodology with dual focuses on ethical principles and dialogue, and(3)the acceptance of life-shortening procedures based on autonomy. While ACP as a public-opinion ethics approach will face challenges in creating forums for discussion, especially on the topic of death, improving proficiency in ethical principles and dialogue-based methodologies among medical professionals may address some of these issues. The extent to which life-shortening procedures should be tolerated remains a significant challenge and necessitates prompt legislative development.
Download full-text PDF |
Source |
---|
Gan To Kagaku Ryoho
December 2024
Graduate School of Health Sciences, Niigata University.
Since the 1970s, medical ethics has evolved from an informal approach to a more structured public discourse. The 4 principles proposed by Beauchamp and Childress in 1979 have gained international recognition and are useful for organizing ethical issues. However, this methodology has its limitations, and dialogue-based ethics are becoming increasingly important.
View Article and Find Full Text PDFRadiat Prot Dosimetry
November 2024
Department of Radiobiology, Institute for Environmental Sciences (IES), 1-7 Ienomae, Obuchi, Rokkasho-mura, Kamikita-gun, Aomori 039-3212, Japan.
CNS Drugs
October 2024
Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
The life shortening nature of Friedreich Ataxia (FRDA) demands the search for therapies that can delay, stop or reverse its relentless trajectory. This review provides a contemporary position of drug and gene therapies for FRDA currently in phase 1 clinical trials and beyond. Despite significant scientific advances in the specificity of both compounds and targets developed and investigated, challenges remain for the advancement of treatments in a limited recruitment population.
View Article and Find Full Text PDFExp Hematol Oncol
August 2024
Institute of Biochemistry and Cell Biology (IBBC- CNR), Via Ercole Ramarini, 32 Monterotondo Scalo, 00015, Rome, Italy.
Background: Ataxia-telangiectasia (A-T) is a rare autosomal recessive multi-system and life-shortening disease, characterized by progressive cerebellar neurodegeneration, immunodeficiency, radiation sensitivity and cancer predisposition, with high incidence of leukemia and lymphoma. A-T is caused by mutations in the gene encoding for ATM protein that has a major role in maintaining the integrity of the genome. Because there are no cures for A-T, we aimed to tackle immunodeficiency and prevent cancer onset/progression by transplantation therapy.
View Article and Find Full Text PDFClin Pediatr (Phila)
July 2024
Department of Rehabilitation Sciences, Faculty of Humanities and Social Sciences, Humboldt-Universität zu Berlin, Berlin, Germany.
This study provides prevalence and mortality data for 0- to 19-year-old children and adolescents with medically documented life-threatening and life-shortening diagnoses in Germany. A secondary data analysis of more than 12 million insured persons documented by the statutory health insurance funds in Germany from 2014 to 2019 was conducted in collaboration with the German Association of Statutory Health Insurance Funds (GKV-SV) and the Institute for Applied Health Research Berlin (InGef), whose data sets vary in collection methods. Diagnosis prevalence and mortality were calculated based on selected International Classification of Diseases, 10th Revision (ICD-10) codes reported in inpatient and outpatient care settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!